| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 29, 2026 | How The Bologna Gathering became an ecosystem builder | Alessandro Cillario and Stefano Onofri, co-founders and co-CEOs of Italian startup Cubbit, could easily spend all their time scaling internationally. Instead, alongside building one of Europe's leading sovereign cloud companies, they've inv... |
| Jul 22, 2026 | NSG Bio Accelerates Breakthrough Biotech Innovation in Singapore | New initiative under NSG Bio Tomorrow will support promising startups developing next-generation approaches in respiratory and neonatal care
SINGAPORE, July 22, 2026 /PRNewswire/ -- The NSG Bio Tomorrow initiative aims at supporting emergin... |
| May 26, 2026 | Game-changing accelerator which has helped life science start-ups raise £120m welcomes new cohort | Six exciting early-stage ventures secure coveted spots on Babraham Research Campus’ Accelerate@Babraham pre-seed company support programme.
Cambridge, UK, 26th May 2026: Babraham Research Campus is delighted to announce the 2026 Accelerate@... |
| Apr 23, 2026 | Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights | Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025.
Chiesi reported €3.625 billion in consolidated revenues, a... |
| Feb 17, 2026 | Rome-based VoiceMed reaches €1 million in total funding; launches pilot for early detection of chronic respiratory diseases | VoiceMed, a Rome-based digital health company developing voice-based solutions for remote monitoring of chronic respiratory issues, today announced that it has reached €1 million in total funding, completing its first funding round.
The com... |
| Dec 12, 2025 | Болезням прописали инструкцию | |
| Nov 11, 2025 | PDA Releases Three New Foundational Documents to Advance Aseptic Processing and Sterilizing Filtration Practices | These documents reflect PDA's ongoing dedication to providing the pharmaceutical industry with high-quality, practical resources that promote excellence in sterile product manufacturing.
BETHESDA, Md., Nov. 11, 2025 /PRNewswire-PRWeb/ -- Th... |
| Jan 13, 2025 | How to Overcome Trial Planning and Patient Recruitment Challenges, Upcoming Webinar Hosted by Xtalks | www.citeline.com
In this free webinar, learn how to overcome internal and external challenges in clinical planning and recruitment. Attendees will gain insight into how to secure management buy-in and budget. The featured speakers will shar... |
| Aug 22, 2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| Jun 17, 2024 | InnoStars Connect health innovation program applications are now open | Startups, researchers from small and medium-sized enterprises (SMEs), universities, and hospitals in Latvia are invited to apply to InnoStars Connect, a challenge-based program for emerging European countries, by June 30th.
This program pro... |
| Apr 22, 2024 | Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices | Highlights from Chiesi Group's 2023 financial report:
Sales increased to over €3 billion, up 10% compared to 2022 (+12% @CER), driven by the Rare business unit growth (65% @CER), and steady growth of all products in all its Regions
24% of 2... |
| Apr 12, 2024 | Empower Her - 38 Organizations are recognized as 'Best Workplaces for Women™ in Greater China 2024', by Great Place To Work® | SHANGHAI, April 12, 2024 /PRNewswire/ -- Great Place To Work® takes pride in announcing the 38 'Best Workplaces for Women™ in Greater China 2024'.
The Best Workplaces for Women™ stand above competitors by creating trustworthy organizations ... |
| Aug 7, 2023 | Chiesi Group acquires Santhera’s idebenone assets | |
| Mar 7, 2023 | Affibody and Chiesi Group collaborate to develop and commercialize innovative treatments for respiratory diseases | Affibody and Chiesi Group collaborate to develop and commercialize innovative treatments for respiratory diseases
Tue, Mar 07, 2023 10:23 CET Report this content
Affibody and Chiesi Group will collaborate closely to develop novel Affibody® ... |
| Jan 9, 2023 | Chiesi Farmaceutici Acquires Amryt Pharma, for Up To US$1.48 Billion | Chiesi Farmaceutici acquired Amryt Pharma Plc (“Amryt”) (Nasdaq: AMYT), a Dublin, Ireland-based commercial-stage biopharmaceutical company.
The total transaction value at close was approximately US$1.25 billion in upfront consideration, plu... |
| Jan 8, 2023 | Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc | Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
- Transaction expands Chiesi's rare disease medicine portfolio
- All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on c... |
| Dec 2, 2022 | Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician Recruitment and Retention | As a Certified B Corporation™, Chiesi deepens ASHP partnership to fund educational efforts designed to address the pharmacy technician shortage and support pharmaceutical professionals.
/EIN News/ -- CARY, N.C., Dec. 02, 2022 (GLOBE NEWSWIR... |
| Nov 29, 2022 | Chiesi USA Announces Publication of Health Economics Analysis of Selective Early Rescue Surfactant Administration vs. Standard Surfactant Administration for Premature Infants with Respiratory Distress Syndrome | This cost-consequence analysis suggests selective early rescue surfactant administration strategies are associated with a lower healthcare burden in premature infants with RDS.
/EIN News/ -- CARY, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Chi... |
| Oct 17, 2022 | Chiesi USA Chosen as One of Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals | Chiesi USA recognized for its dedication to ensuring that employee voices are heard and valued
CARY, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international re... |
| Oct 3, 2022 | Chiesi USA Partners with Durham Bulls to Donate $15,000 to Three Triangle Nonprofits | CARY, N.C., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), a Cary-based specialty pharmaceutical company, felt like part of the team as the company concluded its presenting strikeout partnership with the Durham Bulls minor league... |
| Sep 22, 2022 | Chiesi is Recertified as a B Corp and Sets New Tougher Objectives for Action by 2025 | The Group has increased its B Impact score by 16.3 points, with 103.8 out of 200 compared to its first certification in 2019The recertification process by B Lab identifies further focus for action and continuous improvement.
CARY, N.C., Sep... |
| Sep 6, 2022 | Chiesi USA Reports Progress in ASHP Foundation’s Pharmacy Leadership Scholars Program | Chiesi USA sponsored the innovative ASHP Foundation Pharmacy Leadership Scholars program, awarding $50,000 in grants to five early-stage pharmacist researchers
CARY, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S.... |
| Jul 25, 2022 | Chiesi Group joins White House pledge to decarbonize healthcare sector | Chiesi Group signed the HHS Health Care Sector Climate Pledge to achieve even greater progress on climate resilienceThe White House cited Chiesi’s leadership in exceeding the pledge by tackling emissions from fluorinated gases used in commo... |
| Jul 14, 2022 | Chiesi tracks actions taken for a healthier, more sustainable future | Chiesi’s Annual and Sustainability Report 2021 is released today;Progress toward business, environmental and social targets is strong;Company is joining forces with all stakeholders to advance sustainable healthcare.
CARY, N.C., July 14, 20... |
| Jun 1, 2022 | Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL® (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice | The CAMEO registry, an ongoing study to provide real-world data on KENGREAL® (cangrelor), has published interim results in the Journal of the American Heart Association.This analysis from CAMEO is the first analysis of its kind to describe ... |
| Apr 11, 2022 | Chiesi Group Continues to Grow In 2021 | Chiesi Group turnover of €2.42bn supported by strong international growth of 8.6%Growth across global markets, with U.S. up more than 10% and China up 22%Continued focus on innovation: Chiesi invests nearly 20% of turnover in R&D in 202... |
| Mar 16, 2022 | Chiesi USA donates more than $815,000 to local communities and nonprofits in 2021 | CARY, N.C., March 16, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, contributed more than $815,000 in 2021 through its Chiesi in the Community (CITC) corporate social responsibility (C... |
| Feb 24, 2022 | Chiesi USA certified as a Great Place to Work® in 2021 | Employee-led assessment affirms Chiesi USA’s strong performance in culture, leadership, values and trust
CARY, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, has earned t... |
| Jan 25, 2022 | Chiesi USA Announces New Publication of Post Hoc Analysis on Timing of Ischemic Events in Cardiac Patients and Role of KENGREAL® (cangrelor) in Reducing Risk | Post hoc analysis of the CHAMPION PHOENIX clinical trial demonstrates that the majority of ischemic events occurred early in percutaneous coronary intervention (PCI), and KENGREAL® (cangrelor) treatment significantly reduced these events in... |
| Jan 25, 2022 | Chiesi USA Announces New Publication of Post Hoc Analysis on Timing of Ischemic Events in Cardiac Patients and Role of KENGREAL® (cangrelor) in Reducing Risk | Post hoc analysis of the CHAMPION PHOENIX clinical trial demonstrates that the majority of ischemic events occurred early in percutaneous coronary intervention (PCI), and KENGREAL® (cangrelor) treatment significantly reduced these events in... |
| Jan 24, 2022 | Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2022 | Chiesi USA celebrates seven consecutive years of recognition from the Top Employers Institute
CARY, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international res... |
| Jan 24, 2022 | Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2022 | Chiesi USA celebrates seven consecutive years of recognition from the Top Employers Institute
CARY, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international res... |
| Dec 20, 2021 | A new clinical framework redefines the diagnosis of COPD Exacerbations | The recommendations of an international expert panel to update the definition and severity classification of chronic obstructive pulmonary disease (COPD) exacerbations will be presented by Professor Bartolome R. Celli at the 2021 Internatio... |
| Dec 20, 2021 | A new clinical framework redefines the diagnosis of COPD Exacerbations | The recommendations of an international expert panel to update the definition and severity classification of chronic obstructive pulmonary disease (COPD) exacerbations will be presented by Professor Bartolome R. Celli at the 2021 Internatio... |
| Nov 8, 2021 | Chiesi USA Promotes Polly Petrino to VP, Finance and Member of Leadership Team | Finance leader with more than 20 years of expertise will lead finance, administrative and contracting functions
CARY, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), a Cary-based specialty pharmaceutical company, has announc... |
| Nov 8, 2021 | Chiesi USA Promotes Polly Petrino to VP, Finance and Member of Leadership Team | Finance leader with more than 20 years of expertise will lead finance, administrative and contracting functions
CARY, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), a Cary-based specialty pharmaceutical company, has announc... |
| Oct 15, 2021 | Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease | CARMIEL, Israel and BOSTON, Oct. 15, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic p... |
| Oct 11, 2021 | Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease | CARMIEL, Israel and BOSTON, Oct. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic p... |
| Oct 6, 2021 | Chiesi USA Donates nearly $15,000 to Three Triangle Nonprofits through Partnership with Durham Bulls | Partnership spotlights Triangle nonprofits as the true champions with Chiesi as the 2021 presenting strikeouts sponsor
CARY, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- As the Durham Bulls took down the Norfolk Tides on September 12, Chiesi USA... |
| Aug 10, 2021 | Chiesi USA Announces Publication of Cost-Consequence Analysis of KENGREAL® (cangrelor) in Cardiac Patients at High Risk of Complications Following PCI in the American Journal of Cardiovascular Drugs | CARY, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the publication of a cost-consequence analy... |
| May 1, 2021 | Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease | |
| Apr 21, 2021 | Chiesi Group receives European Marketing Authorization for Trimbow® inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) delivered through NEXThaler, an extrafine formulation fixed triple combination therapy for the treatment of moderate to severe COPD | Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an inhaled corticosteroid (ICS) / long-acting... |
| Mar 18, 2021 | Chiesi Group announces performance growth in 2020 | Chiesi Group currently employs 6,389 people worldwide, 2,119 of whom are in Italy, and has a turnover of €2.229 billion.
Chiesi’s business comprises 30 affiliates, seven research centers, three production sites and a commercial presence in ... |
| Mar 17, 2021 | Chiesi USA, Inc. announces Commercial Availability of Bronchitol® (mannitol) inhalation powder for improvement in pulmonary function in adult patients with cystic fibrosis | CARY, N.C., March 17, 2021 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the launch of FDA-approved Bronchitol® (mannitol)... |
| Mar 16, 2021 | Chiesi USA Announces Sponsorship of ASHP Foundation’s Pharmacy Leadership Scholars Program | CARY, N.C., March 16, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today its sponsorship of the ASHP Foundat... |
| Mar 1, 2021 | Chiesi USA donates more than $800,000 in 2020 | CARY, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), contributed more than $800,000 in 2020 through its ... |
| Dec 23, 2020 | Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry Disease | |
| Nov 17, 2020 | Chiesi USA, Inc. Supports March of Dimes Eastern North Carolina in Observance of Prematurity Awareness Month | CARY, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), a specialty pharmaceutical company based in Cary, N.C., is proud to once again support March of Dimes in its mission to improve the health and lives of moms and babies d... |
